ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 04 Jan 2022
Last Updated on 31 Aug 2022
A- A+
Tyrosine Kinase Inhibitors for treating ALK-mutation-positive advanced non-small-cell lung cancer Guidance is outdated and has been withdrawn on 12 July 2022. The Plain English Summary (PES) has been updated on 31 August 2022.
Treatments for ALK mutation-positive advanced NSCLC PES (Updated 31 Aug 22) TKIs for ALK mutation-positive advanced NSCLC (Withdrawn 12 Jul 22)